What is iRepertoire?
iRepertoire operates at the intersection of immunology and advanced genomics, providing specialized TCR and BCR sequencing solutions. By offering a comprehensive suite of services—ranging from bulk immune repertoire sequencing to single-cell V(D)J analysis—the company enables researchers to conduct high-resolution biomarker discovery. Their platform is instrumental in addressing complex clinical challenges, including autoimmune disorders, infectious diseases, and the rapidly evolving field of immuno-oncology. Founded by immunologists, the company distinguishes itself through a commitment to reproducible data and scientific partnership, effectively bridging the gap between raw sequencing output and actionable clinical insights.
How much funding has iRepertoire raised?
iRepertoire has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in iRepertoire
PPP
Public-Private Partnership
What's next for iRepertoire?
With this late-stage capital, iRepertoire is poised to scale its operational infrastructure and expand its global footprint. The strategic focus will likely shift toward enhancing its data analytics capabilities and broadening the application of its immune repertoire analysis in clinical trial settings. As the demand for precision medicine continues to rise, the company is strategically positioned to leverage its technological moat to secure a larger share of the diagnostic and therapeutic development market. Future growth will be driven by the integration of its sequencing solutions into standard clinical workflows, further cementing its role as a critical partner in the development of next-generation immunotherapies.
See full iRepertoire company page
